Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common ...

1 Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands 2 Department of Rheumatology and Clinical Immunology, ...

The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target ...

Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...

Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue ...

Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...

Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...

Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled ...

Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...

Department of Rheumatology, Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, University of Tel Aviv, Israel Correspondence to: Dr O Elkayam, Department of Rheumatology, Tel ...

Background B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune diseases, generating impetus to develop alternate strategies that provide activity with rapid onset and ...

Background Methotrexate is the anchor drug used most widely as monotherapy or combination therapy with other DMARDS & biologics in treatment of RA. It is widely perceived by clinicians to have ...